Scandion Oncology announces share purchase by Board of Directors and Executive Management
Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that members of the Board of Directors and Executive Management have purchased shares in the company.The following share purchases have been reported: Shares purchased Total shareholding Peter Chairman of the Board 6,500 59,565HøngaardAndersenJørgen Vice-chairman of the Board 15,000 425,629BardenflethChristian Board member 10,000 10,000VindingThomsen